You are viewing a preview of...
AUP-55 - A Lactic Acid Bacterial Treatment for Ovarian Cancer, Bladder Cancer, and Peritoneal Carcinomatosis
Aurealis pre-clinical stage asset AUP-55 consists of genetically engineered lactic acid bacteria for the treatment of ovarian cancer, peritoneal carcinomatosis and bladder cancer. In ovarian cancer models in mice, treatment with AUP-55 resulted in 91.3 % survival and lower tumour load compared to 0 % survival and massively increased tumour load in untreated subjects.
Aurealis Therapeutics have provided the following sources to better demonstrate the capabilities of AUP-55:
- Product Presentation
- Relevant Publication (Journal of Clinical Oncology)
Log in or create a free account to continue reading